India’s pharmaceutical sector continues to grow rapidly, with the market valued at $50 billion in FY 2023-24. Domestic consumption stands at $23.5 billion, while exports contribute $26.5 billion, solidifying India’s global presence.

The industry benefits from strong government initiatives, including the establishment of seven National Institutes of Pharmaceutical Education & Research (NIPERs) and the “National Policy on Research & Development and Innovation in Pharma-MedTech Sector.”

These efforts aim to foster innovation, enhance regulatory support, and strengthen India’s position as a leader in drug discovery and medical devices.

Amid this evolving landscape, several pharma stocks, including Laurus Labs and Glenmark Pharmaceuticals, have demonstrated impressive 5-year CAGR, making them key players to watch in March 2025.

Top 10 Pharma Sector Stock List In March 2025 – 5 Year CAGR Basis

Note: The list of top pharma stocks in India listed in the stock market here are sorted as per the 5-yr CAGR as of March 3, 2025.

Overview of the 5 Best Pharma Company Stocks for March 2025

1. Laurus Labs

Laurus Labs is a leading pharmaceutical and biotechnology company specialising in APIs, formulations, and synthesis services. It focuses on innovation-driven growth in segments like antiretrovirals, oncology, and custom synthesis.

Laurus Labs’ Q3 FY25 EBITDA margin expanded by 500 basis points to 20.2%, the highest since Q4 FY23. Net profit surged to ₹92 crore from ₹23 crore last year, driven by an 18.5% YoY revenue growth to ₹1,415 crore.

Key metrics:

• ROE: 3.93%
• ROCE: 7.95%

2. Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals is a global pharmaceutical company specialising in generics, specialty, and over-the-counter medicines. It focuses on innovation-driven research in dermatology, respiratory, and oncology segments.

Glenmark Pharmaceuticals reported a strong recovery in Q3FY25, posting a net profit of ₹347.9 crore compared to a net loss of ₹351.3 crore last year. Revenue surged 35.1% YoY to ₹3,387.6 crore, reflecting robust operational performance.

Key metrics:

• ROE: -16.98%
• ROCE: 11.12%

3. Sun Pharmaceutical Industries Ltd

Sun Pharmaceutical Industries is the world’s fourth-largest specialty generic pharmaceutical company and India’s top pharma company. It focuses on developing, manufacturing, and marketing a broad range of formulations and APIs across multiple therapeutic segments.

Sun Pharmaceutical Industries reported a 15% YoY rise in consolidated net profit to ₹2,903.4 crore in Q3 FY25. Revenue grew 10% YoY to ₹13,675.5 crore, driven by strong performance in domestic and emerging markets.

Key metrics:

• ROE: 15.15%
• ROCE: 16.58%

4. Cipla Ltd

Cipla is a leading global pharmaceutical company focused on developing affordable and high-quality medicines across various therapeutic areas. It specialises in respiratory, anti-retroviral, urology, and chronic disease segments, with a strong presence in over 80 countries.

Cipla reported a 49% YoY surge in consolidated net profit to ₹1,571 crore in Q3 FY25. Revenue grew 7% to ₹7,073 crore, driven by strong operational performance.

Key metrics:

• ROE: 21.23%
• ROCE: 15.54%

5. Zydus Lifesciences Ltd

Zydus Lifesciences is a leading Indian pharmaceutical company focused on innovation-driven healthcare solutions, including generics, biologics, and vaccines. It has a strong presence in global markets, specialising in critical therapies like cardiovascular, diabetes, and oncology.

Zydus Lifesciences reported a 30% YoY rise in net profit to ₹1,023 crore in Q3 FY25, supported by strong forex gains. Revenue grew 17% to ₹5,269 crore, reflecting robust business performance.

Key metrics:

• ROE: 20.91%
• ROCE: 19.44%

Pharmaceutical Companies Sorted by Debt-to-Equity Ratio

Note: The list of top pharma stocks in India listed in the stock market here are sorted as per the Debt-to-Equity as of March 03, 2025.

Best Pharma Sector Stock List In India In March 2025 – Net Profit Margin Basis

Note: The list of top pharma stocks in India listed in the stock market here are sorted as per the net profit margin as of March 3, 2025.

Conclusion

The Indian pharmaceutical sector has shown strong growth, supported by domestic demand, exports, and government initiatives. Based on key financial metrics, companies like Laurus Labs, Glenmark Pharmaceuticals and others have demonstrated solid performance over the past five years.

The data highlights their financial stability and market standing, providing insights into their past growth trends. Investors and stakeholders can use these metrics to assess the sector’s recent performance within the evolving industry landscape.

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

NTPC has achieved its fastest-ever 400 BU power generation milestone in FY25 within 335 days, 12 days earlier than last year, showcasing its efficiency and ongoing expansion in renewable energy projects.

NTPC Sets a New Benchmark 

NTPC Ltd., India’s largest power utility, has achieved a historic milestone by generating 400 Billion Units (BU) of electricity in the fastest time ever—just 335 days into the financial year 2024-25. This marks a significant improvement over the previous year when the same benchmark was reached 12 days later, on March 13, 2024.

NTPC’s Growing Capacity and Expansion Plans

NTPC currently holds an impressive installed power generation capacity exceeding 77 GW. To further strengthen its position in the energy sector, the company is actively expanding, with 29.5 GW of additional capacity under construction.

A key focus area in this expansion is renewable energy, contributing 9.6 GW to the upcoming projects. By 2032, NTPC aims to reach 60 GW of renewable energy capacity as part of its long-term sustainability goals.

Diversification and Commitment to Sustainability

Beyond traditional power generation, NTPC is venturing into various new and emerging sectors. These include:

• E-mobility solutions to support India’s transition to clean transportation.
• Battery storage and pumped hydro storage to enhance grid stability and energy efficiency.
• Waste-to-energy and green hydrogen projects, contributing to sustainable power solutions.
• Nuclear power initiatives to diversify its energy portfolio.
• Participation in power distribution bidding for Union Territories, further strengthening its presence in the power sector.

NTPC’s Share Price Performance

NTPC’s share price was in focus as the stock traded at ₹308.70 at 11:50 AM on the NSE, marking a decline of 0.88% from its previous close of ₹311.45. The stock opened at ₹311.30, touched an intraday high of ₹312.70, and dropped to a low of ₹307.70.

Conclusion

NTPC’s record-breaking power generation performance in FY25 highlights its role as a crucial player in India’s energy sector. With ambitious plans for expansion and sustainability, the company remains committed to driving India’s energy transition while maintaining its leadership in power generation.

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Dalmia Bharat Ltd has announced a strategic ₹3,520 crore investment to expand its cement production capacity in Karnataka and Maharashtra. This move includes a new clinker and grinding unit at its Belgaum plant and a greenfield grinding unit in Pune, boosting its total capacity to 55.5 MnTPA.

Dalmia Bharat’s share price traded at ₹1,695, up 0.43% at 11:30 AM on the BSE.

Dalmia Bharat Cement Capacity Expansion Plans 

Dalmia Bharat Ltd., a leading cement manufacturer, has announced a major investment of ₹3,520 crore in Maharashtra and Karnataka to enhance its cement production capacity.

The expansion, funded through a mix of debt and internal accruals, will add significant capacity to meet the increasing infrastructure demand in Western and Southern India.

Strategic Expansion Plan

As part of this initiative, Dalmia Bharat will establish:

• A 3.6 million tonnes per annum (MnTPA) clinker unit and a 3 MnTPA grinding unit at its existing Belgaum plant in Karnataka.
• A new greenfield split grinding unit with a 3 MnTPA capacity in Pune, Maharashtra.

With these additions, the company’s total installed cement capacity will increase to 55.5 MnTPA, including its ongoing 2.9 MnTPA expansion in Assam and Bihar. The new units are expected to be commissioned by Q4 FY27, as per news reports.

Strengthening Market Presence

The expansion is designed to strengthen Dalmia Bharat’s market share in key regions:

• Belgaum Unit: Will serve the underserved Southern Maharashtra markets while improving its penetration in Karnataka.
• Pune Grinding Unit: Will cater entirely to the untapped Western Maharashtra markets, reinforcing the company’s presence in the western region.

Conclusion

Dalmia Bharat’s ₹3,520 crore investment marks a significant step in its expansion strategy, enhancing its production capacity in Maharashtra and Karnataka. This development is part of the company’s broader vision to increase its cement output, supporting infrastructure growth in key markets.

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Bandhan Bank’s share price declined by 1.08% on March 3, 2025, closing at ₹139.67, down ₹1.52 from the previous close of ₹141.19. The stock opened at ₹142.10 and reached an intraday high of ₹144.19, before slipping to a low of ₹138.90. The stock gained close to 4% in the last 2 trading sessions.

RBI’s Move Boosts Bandhan Bank’s Lending Capacity

Bandhan Bank’s share price gained recently as the Reserve Bank of India (RBI) restored risk weights for bank lending to Non-Banking Financial Companies (NBFCs) from 125% to 100%, effective April 1, 2025. This decision reduces the capital required by banks to lend to NBFCs, allowing for increased credit flow to the sector.

Additionally, microfinance loans provided by banks have been exempted from higher risk weights, meaning Bandhan Bank—being a key player in the microfinance segment—will benefit significantly. With reduced risk weights, the bank can allocate capital more efficiently, expand its microfinance lending, and improve profitability.

Bandhan Bank Q3 FY25 

Bandhan Bank reported a 20.07% year-on-year (YoY) increase in total deposits, reaching ₹1,40,999 crore in the quarter ended December 31, 2024, compared to ₹1,17,422 crore in the same quarter last year. However, on a quarter-on-quarter (QoQ) basis, deposits declined 1.1% from ₹1,42,510 crore recorded in September 2024.

Bulk deposits saw a 31% YoY rise to ₹44,204 crore, though they declined 3.7% QoQ. The retail to total deposits ratio stood at 68.6% in December 2024, down from 71.3% a year ago.

CASA deposits increased 5.5% YoY to ₹44,735 crore, but declined 5.4% QoQ, reflecting some seasonal variations. While the bank showed solid yearly growth, the slight sequential decline in deposits highlights short-term fluctuations in deposit mobilisation.

Conclusion

Bandhan Bank’s recent share price movement reflects a mix of profit booking and strong investor sentiment driven by favourable regulatory changes.

While the RBI’s decision on risk weights is expected to enhance the bank’s lending capacity and long-term growth prospects, short-term fluctuations in deposits and stock performance remain key factors to monitor.

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Reliance Industries shares declined for the second straight session amid delays in battery production under India’s PLI scheme, with concerns over missed deadlines and potential penalties, as per Economic Times news reports.

RIL’s Missing Battery Production Deadline

A unit of Reliance Industries Ltd., led by billionaire Mukesh Ambani, is under scrutiny for failing to establish a battery cell manufacturing facility under the Indian government’s initiative to boost domestic production.

Reliance New Energy Ltd., alongside Rajesh Exports, risks financial penalties for missing key project milestones aimed at reducing import dependence for advanced chemistry cell batteries, as per Economic Times news report.

Penalties and Compliance Issues

Reliance New Energy and Rajesh Exports were awarded contracts in 2022 as part of India’s Production-Linked Incentive (PLI) program, which supports domestic battery manufacturing. Under this scheme, companies were expected to achieve a minimum committed production capacity and local value addition of 25% within 2 years, increasing to 50% within 5 years.

However, both companies have failed to meet their respective deadlines and could face fines up to ₹1.25 billion ($14.3 million) for the delays. The penalties are relatively minor for Reliance, but the inability to meet production targets raises questions about India’s ambitious plan to rival China in battery production and EV technology.

Challenges in the PLI Scheme

The PLI scheme has seen mixed results across industries. While it has successfully boosted local smartphone assembly, the battery production sector has struggled due to high investment costs and technological challenges. These issues have slowed progress, impacting India’s efforts to develop domestic battery manufacturing capabilities.

On the other hand, Ola Cell Technologies, a subsidiary of Ola Electric, has made significant strides under the program. The company began trial production in March 2024 and expects to commence commercial lithium-ion cell production between April and June 2025. Ola Electric confirmed in a statement that they are on track to meet the government’s set targets.

Share Price Performance

Reliance Industries Limited’s share price declined 3.12% to ₹1,162.65 on March 3, 2025, marking its second consecutive session of losses. The stock opened at ₹1,204.00 and hit an intraday high of ₹1,206.45 before dropping to a low of ₹1,161.15.

Conclusion

Reliance New Energy’s failure to meet PLI deadlines signals the difficulties in scaling up battery cell production despite government incentives. While Ola Electric has made progress, broader industry challenges, including high costs and shifting global market conditions, continue to affect India’s ambitious plans for self-reliant battery manufacturing.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Paytm’s parent company, One 97 Communications, is under regulatory focus after the Enforcement Directorate issued a show cause notice over alleged FEMA violations amounting to ₹611 crore. The case involves investments in subsidiaries, with Paytm actively seeking legal resolution.

Details of the ED Notice to Paytm

The notice, dated February 27, 2025, pertains to specific foreign exchange rule violations identified by the ED. According to a disclosure made by Paytm to the Bombay Stock Exchange (BSE) on March 2, 2025, the company received the notice on February 28, 2025.

The ED has reportedly flagged non-compliance amounting to:

• ₹245 crore in OCL.
• ₹345 crore in Little Internet.
• ₹20.9 crore in Nearbuy India.

The alleged violations are linked to certain investment transactions in these entities.

Paytm’s Response

In its official statement, OCL has confirmed that it is seeking legal counsel to determine the appropriate course of action. The company has also assured that it is taking necessary steps to resolve the matter in line with the applicable laws and regulatory processes, as per news reports.

Moreover, Paytm clarified that the compliance issues in Little Internet and Nearbuy India stem from a period before these companies were acquired by Paytm. The fintech giant had acquired both firms in 2017, merging them into a single entity. Before the acquisition, Little Internet was backed by Tiger Global Management and Elevation Capital, securing around $50 million in equity funding.

Meanwhile, Nearbuy India, co-founded by Ankur Warikoo, had received $22 million in funding from Peak XV Partners (formerly Sequoia India).

Paytm’s Share Price Performance

Paytm’s parent company, One 97 Communications Limited, saw its share price decline by 1.80% to ₹702.10 AT 9:40 AM on the NSE as of March 3, 2025 . The stock opened at ₹700, hit a high of ₹709.60, and dipped to a low of ₹683.55.

Conclusion

As Paytm works to address the allegations, this situation underscores the importance of regulatory compliance in the rapidly evolving fintech space. The coming weeks will be critical for Paytm as it engages with legal and regulatory authorities to resolve the matter.

Investors and stakeholders will be keenly watching for updates, as any further developments could have significant implications for the company’s stock performance and overall business operations.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

This week, several major companies are making significant corporate moves that could impact investors. From dividend payouts and stock splits to bonus issues, it’s essential to stay informed about these actions and how they may affect your portfolio and investment strategy.

Upcoming Bonus Issue This Week

Upcoming Dividend Issue This Week

 

Upcoming Stock Split This Week

Eligibility for Corporate Actions This Week

• Metro Brands

Metro Brands is distributing a dividend of ₹14.50 per share. Investors must hold shares before March 6, 2025, to be eligible for the dividend payout.

• SBI Life Insurance

SBI Life Insurance is offering a dividend of ₹2.70 per share. To receive the payout, investors must own shares before March 6, 2025.

• Vantage Knowledge

Vantage Knowledge has announced a 2:1 bonus issue. Shareholders must hold shares before March 4, 2025, to receive 2 bonus shares for every 1 share held.

• Mangalam Global

Mangalam Global has declared a 2:1 stock split. Shareholders must hold the stock before March 3, 2025, to receive additional shares as per the split ratio.

Conclusion

This week brings several significant corporate actions, including bonus issues, stock splits, and dividends, from companies like Metro Brands, SBI Life Insurance, Vantage Knowledge, and Mangalam Global. Investors should take note of the ex-dates to ensure eligibility for these benefits.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.